Edgewood Oncology, a Brookline, MA-based clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, raised $20M in Series A funding.
The round was led by Alta Partners.
The company intends to use the funds to advance the clinical development of BTX-A51 in acute myeloid leukemia (AML) and a precision medicine approach to breast cancer.
Led by CEO David N. Cook, Edgewood Oncology is a clinical-stage biotechnology company advancing BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. It is a novel small molecule, multi-kinase inhibitor that synergistically co-targets master regulators of cancer to activate programmed cell death, or apoptosis. BTX-A51 holds promise in acute myeloid leukemia and genetically-defined solid tumors, which are the focus of ongoing clinical programs.
Commenting on the news, David N. Cook said: “We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients. We look forward to further developing this compound using a precision medicine approach in patient populations who lack effective treatment options.”
FinSMEs
25/03/2024